Chest
Clinical Investigations: MalignanciesElevation of Interleukin-10 Levels in Malignant Pleural Effusion
Section snippets
MATERIALS AND METHODS
Pleural fluid and peripheral blood were simultaneously obtained from 21 patients with newly diagnosed neoplastic pleural effusions. Major clinical characteristics of these 21 patients are summarized in Table 1. All patients had histocytologically proved neoplastic pleural effusion.
Cytokine analysis was performed by using the ELISA method. Peripheral blood samples and pleural effusions were centrifuged at 1,000g for 15 min at 4°C. The supernatant was collected and stored at −70°C in aliquots of
RESULTS
Cytokine analyses of all specimens from the patients revealed that IL-4 and IL-12 were either undetectable or below minimal detectable concentration of the ELISA kits both in the effusions and blood. Most of the patients had detectable IL-10 in their effusion and blood, and the levels in the pleural effusion were significantly higher than in blood (p=0.0001). The cytokine data are shown in Table 1.
The characteristics of the lymphocyte subpopulations in peripheral blood and pleural effusions are
DISCUSSION
In the present study, the percentages of CD3+/CD4+ (helper T cell) lymphocytes were significantly higher in the pleural fluid than in the peripheral blood of patients suffering from malignant pleural effusions. The same data have been reported in neoplastic and tuberculosis pleural effusions previously.14, 15, 16, 17, 18 The finding that a decrease in pleural CD3+/CD8+ (suppressor T cell) lymphocytes in neoplastic pleural effusion has not been reported before (to our knowledge). Because most of
References (22)
- et al.
Cytokine content in pleural effusion—comparison between tuberculous and carcinomatous pleurisy
Chest
(1991) - et al.
Interleukin-12 is chemotactic for natural killer cells and stimulates their interaction with vascular endothelium
Blood
(1994) Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes
Blood
(1994)- et al.
Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion
Chest
(1993) - et al.
High level of interferon gamma in tuberculous pleural effusion
Chest
(1988) - et al.
NK cells in carcinomatous and tuberculous pleurisy—phenotypic and functional analyses of NK cells in peripheral blood and pleural effusions
Chest
(1987) The pleura
Am Rev Respir Dis
(1988)Pleural diseases
Dis Mon
(1992)- et al.
Pulmonary natural killer cell activity is reduced in patients with bronchogenic carcinoma
Am Rev Respir Dis
(1987) - et al.
Induction of killer cells from lymphocytes in pleural effusion of advanced lung cancer patients
Jpn J Cancer Res
(1990)
Pleural cell biology in health and disease
Am Rev Respir Dis
Cited by (60)
PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non–Small Cell Lung Cancer Patients with Malignant Pleural Effusion
2018, Journal of Thoracic OncologyCitation Excerpt :Malignant pleural effusion is a common complication of lung cancer. Chen et al. reported that tumor-induced immunosuppression could be observed in pleural effusion.4 However, PD-L1 expression in pleural effusion cells has not been reported.
Immune checkpoint inhibitors for nonsmall cell lung cancer treatment
2017, Journal of the Chinese Medical AssociationCitation Excerpt :Although the immune system plays an important role in recognizing, controlling, and eradicating cancer, cancer induces immunosuppression through several mechanisms that may suppress effective antitumor immunity, including but not limited to: (1) secretion of immunosuppressive cytokines; (2) loss of major histocompatibility complex antigen expression; (3) and programmed cell death protein 1/programmed cell death protein 1 ligand (PD-1/PD-L1) interaction of tumor cells with immune cells.2–6 In the past, immunotherapy has had minimal success in lung cancer treatment, which was attributed in part to the belief that lung cancer is nonimmunogenic.7–11 Most patients present with advanced disease and are immunosuppressed, as documented by decreased lymphocyte counts and cytotoxic function seen in this patient population.8,11–13
Malignant pleural effusion: current understanding and therapeutic approach
2024, Respiratory ResearchMicroRNAs Present in Malignant Pleural Fluid Increase the Migration of Normal Mesothelial Cells In Vitro and May Help Discriminate between Benign and Malignant Effusions
2023, International Journal of Molecular SciencesS100A9 Regulated M1/M2 Macrophage Polarization in Interleukin-10-Induced Promotion of Malignant Pleural Effusion
2023, Journal of Immunology Research